INDUSTRY SESSIONS PROGRAM
– Industry sessions program –
January 22, 2021
3:15 pm – 4:15 pm SGT Asia (Singapore time)
SGLT2i – Met and Unmet needs
January 22, 2021
5:45 pm – 6:45 pm CET Europe/Middle/East (Madrid time)
SGLT2 inhibitors in heart failure – focus on EMPEROR-Reduced
January 22, 2021
5:45 pm – 6:45 pm CST Americas (Chicago time)
Management of hyperkalemia and enablement of guideline-recommended RAASi therapy in the diabetic cardiorenal patient – practical considerations
January 23, 2021
5:45 pm – 6:45 pm SGT Asia
(Singapore time)
Making the cardiorenal connection with SGLT2 inhibitors
January 23, 2021
5:45 pm – 6:45 pm CET Europe/Middle/East (Madrid time)
Totality of evidence on renal benefits in CRM trials – focus on SGLT2 inhibitors
January 23, 2021
8:00 pm – 9:00 pm CET Europe/Middle/East (Madrid time)
Innovative device technologies for the management of Heart Failure & Cardiorenal Syndrome
January 23, 2021
5:45 pm – 6:45 pm CST Americas
(Chicago time)
Managing complications in CKD:
Novel therapies for hyperkalaemia and anaemia
January 24, 2021
5:45 pm – 6:45 pm SGT Asia
(Singapore time)
Getting to the heart of managing heart failure – where is the future?
January 24, 2021
5:45 pm – 6:45 pm CET Europe/Middle/East (Madrid time)
Iron deficiency beyond anemia in cardiorenal patients – interdisciplinary crosstalk
January 24, 2021
5:45 pm – 6:45 pm CST Americas
(Chicago time)
Innovative device technologies for the management of Heart Failure & Cardiorenal Syndrome
